HLA class I antigen loss, tumor immune escape and immune selection

Vaccine. 2002 Dec 19;20 Suppl 4:A40-5. doi: 10.1016/s0264-410x(02)00386-9.


Poor clinical response rates have been observed in the majority of the T cell-based immunotherapy clinical trials conducted to date. One reason might be the presence of abnormalities in HLA class I antigen presentation in malignant lesions. An increased frequency of HLA class I abnormalities has been observed in malignant lesions from patients treated with T cell-based immunotherapy and in lesions which have recurred in patients who had experienced clinical responses following T cell-based immunotherapy. These observations are compatible with the possibility that the outgrowth of a patient's tumor reflects immune selection of tumor cells which have acquired escape mechanisms from immune recognition.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Histocompatibility Antigens Class I / genetics
  • Histocompatibility Antigens Class I / immunology*
  • Humans
  • Immunotherapy
  • Mutation
  • Neoplasms / immunology*
  • Neoplasms / therapy


  • Histocompatibility Antigens Class I